Lauren Schneider, MD
Ophthalmology · Stamford, CTNPI 1518100197
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,563 of the $3,690 with a category attached, or 69.5%. 22 manufacturers reported payments, led by Johnson & Johnson Surgical Vision, Inc. at 40.9% of the total. Reporting peaked in 2019 at $1,946 and has fallen 76.7% since, to $453 in 2025.
Across 107 payments — averaging $34.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$2K
- Alcon$444
- Oyster Point Pharma, Inc.$233
- Tarsus Pharmaceuticals, Inc.$215
- AbbVie$154
- Dompe US, Inc.$149
- plus $985 from 16 others
What the payments were for
- Travel & lodging$1,12731%
- Food & beverage$2,56369%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 4 | $1,509 |
| Alcon | 16 | $444 |
| Oyster Point Pharma, Inc. | 11 | $233 |
| Tarsus Pharmaceuticals, Inc. | 8 | $215 |
| AbbVie(2 entities) | 8 | $154 |
| Dompe US, Inc. | 7 | $149 |
| Sun Pharmaceutical Industries Inc. | 7 | $139 |
| Bausch & Lomb Americas Inc. | 7 | $118 |
| Ocular Therapeutix, Inc. | 7 | $117 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $78 |
| Biotissue Holdings Inc. | 4 | $75 |
| Shire North American Group Inc | 4 | $74 |
| Rayner Intraocular Lenses Limited | 4 | $62 |
| Harrow Eye, LLC | 3 | $58 |
| Thea Pharma Inc. | 2 | $47 |
| Sight Sciences, Inc. | 2 | $46 |
| Kala Pharmaceuticals, Inc. | 2 | $41 |
| Novartis | 2 | $34 |
| Aerie Pharmaceuticals, Inc. | 2 | $33 |
| Carl Zeiss Meditec, Inc. | 1 | $26 |
| Astellas Pharma US Inc | 1 | $21 |
| Johnson & Johnson Vision Care, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis 1-piece IOL$1,465
- Tecnis 3-piece IOL$1,465
- Tecnis Symphony IOL$1,465
- Tecnis Symphony Toric IOL$1,465
How this compares
$3,690 in reported general payments places this provider in the 80th percentile of 279 ophthalmology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 11 | $308,147 |
| RestasisCyclosporine | 92 | $83,370 |
| XiidraLifitegrast | 11 | $17,518 |
| LumiganBimatoprost | 37 | $15,641 |
| CequaCyclosporine | 19 | $13,453 |
| Prednisolone Acetate | 292 | $13,444 |
| LotemaxLoteprednol Etabonate | 25 | $9,059 |
| Fluorometholone | 76 | $6,899 |
| MoxifloxacinMoxifloxacin Hcl | 258 | $6,652 |
| Cyclosporine | 26 | $6,384 |
| Loteprednol Etabonate | 25 | $5,473 |
| CombiganBrimonidine Tartrate/Timolol | 15 | $3,720 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 21 | $3,590 |
| FlarexFluorometholone Acetate | 14 | $3,074 |
| Doxycycline Hyclate | 21 | $2,853 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $149 | $308,14711 claims |
| AbbVieRestasis, Lumigan, Combigan | $154 | $102,731144 claims |
| Bausch & Lomb Americas Inc.Xiidra | $118 | $17,51811 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax, Loteprednol Etabonate | $78 | $14,53250 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $139 | $13,45319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 279 ophthalmology providers in Connecticut.
Other ophthalmology in Stamford
- Gregory GallousisStamford$10K
- Robert FucignaStamford$3K
- John HuangHartford$267K
- Amir CohenNew Haven$266K
- James MurphyHamden$176K
- James TalbotNew Canaan$47K
- Paul KangNew Haven$40K
- Anish ShahNorwich$38K
- Michael KovalFarmington$35K
- Scott SpectorNorwalk$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.